Targeting fundamentals of inflammation, autoimmunity and fibrosis

Granite Bio Debuts With $100 Million of Capital

Granite Bio Debuts With $100 Million of Capital –

Chronic inflammatory diseases represent the most significant cause of death globally. Patients with autoimmune, inflammatory and fibrotic conditions are lacking efficacious treatment options. Granite Bio’s first-in-class assets are designed to target fundamental disease biology.

  • Granite Bio - GRT-001

    GRT-001

    Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.

  • Granite Bio – GRT-002

    GRT-002

    Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and fibrosis.

Two first-in-class therapeutic antibodies GRT-001 and GRT-002

Team:

Granite Bio Team:

  • Patrick Loustau

    Patrick Loustau

    President and Chief Executive Officer
    grey+amolyt icongrey+bms icongrey+novo icon

  • Dominik Hartl

    Chief Medical Officer
    grey+roche icon grey+quell icon grey+novartis icon

  • Gijs van den Brink

    Gijs van den Brink

    Chief Scientific Officer
    grey+roche icongrey+gsk icon grey+forbion icon

  • Kerry Thornton

    Kerry Thornton

    Executive Assistant
    grey+roche icon grey+vector icon

  • Kerstin Renner

    Head Translational Medicine
    grey+ukr icon

  • Sofia Forte

    Sofia Forte

    Head Clinical Operations
    grey+novartis icon

  • Sara Belli

    Sara Belli

    Head Clinical Pharmacology
    grey+roche icon

  • Jean-Nicolas-Schickel

    Jean-Nicolas Schickel

    Head Immunology Discovery
    grey+evotec icongrey+vector icongrey+sanofi icon

  • Georgios Sarantis

    Georgios Sarantis

    Senior Clinical Trial Manager
    grey+novartis icon grey+pfizer icon

  • Maria Sfichiu

    Clinical Trial Manager
    grey+sgs icon grey+idorsia icon

  • Giorgio Ferrari

    Giorgio Ferrari

    Associate Scientist Immunology
    grey+actelion icon

  • Olivia Rudin

    Olivia Rudin

    Senior Research Associate
    grey+cimeio icon grey+limmatech icon grey+idorsia icon

  • Portrait Hasan-Halit Oz

    Hasan-Halit Oz

    Senior Scientist Immunology
    grey+yale icon

  • Portrait Sonia Whitlow

    Sonia Whitlow

    Toxicology Study Monitor

  • Kai Rosport

    Kai Rosport

    CMC, Ridgeline Discovery

  • Magali Muller

    Magali Muller

    Biomarker Expert

Check out our lastest job posts:

Board of Directors:

  • Eliot Forster

    Eliot Forster

    Chairman of the Board

  • Patrick Loustau

    Patrick Loustau

    Granite Bio, President and CEO
    grey+amolyt icongrey+bms icongrey+novo icon

  • Nigel Sheail

    Nigel Sheail

    Versant Ventures
    grey+roche icongrey+novartis icongrey+versant icon

  • Laia Crespo

    Laia Crespo

    Sanofi Ventures
    grey+sanofiventures icon

  • Florian Müllershausen

    Novartis Venture Fund
    grey+nvf icon

  • Markus Enzelberger

    Versant Ventures
    grey+versant icon

  • Rogier Rooswinkel

    Rogier Rooswinkel

    Forbion
    grey+forbion icon

Scientific Advisors:

  • Vishwa Deep Dixit

    Yale University
    Innate Immunity

  • Christopher Denton

    University College London
    Fibrosis

  • Jörg Distler

    Düsseldorf University
    Fibrosis

  • Erica Herzog

    Yale University
    Pulmonary Fibrosis

  • Brian Feagan

    Ontario, Canada
    Inflammatory Bowel Disease

  • Florian Rieder

    Cleveland Clinic
    Inflammatory Bowel Disease

  • Scott Brian Snapper

    Boston/Harvard University
    Inflammatory Bowel Disease

  • Portrait Carrie Sokol

    Carrie Sokol

    Boston/Harvard University
    Type-II Inflammation